Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
McKesson
Boehringer Ingelheim
Julphar
Medtronic

Generated: July 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

Try a free trialSee Plans and Pricing

« Back to Dashboard

Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

Docket ➤ Sign Up Date Filed 1998-10-23
Court District Court, S.D. Florida Date Terminated 2009-03-11
Cause 35:0271 Patent Infringement Assigned To Adalberto Jose Jordan
Jury Demand None Referred To
Parties ANDRX PHARMACEUTICALS, INC.; ELAN CORPORATION, PLC
Patents 3,998,966; 5,637,320
Attorneys Alan B. Clement; Charles A. Weiss; Gerald J. Houlihan; Harvey W. Gurland , Jr.; James Costigan; James R. Barney; Martin P. Endres; Michael J. Flibbert; Michael T. Landen; Philip J. McCabe; Steven Ira Peretz; Terri Ellen Tuchman Meyers; Walter W. Brown
Link to Docket External link to docket
Small Molecule Drugs cited in Elan Corporation v. Andrx Pharmaceutical
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for Elan Corporation v. Andrx Pharmaceutical (S.D. Fla. 1998)

Date Filed Document No. Description Snippet Link To Document
1998-10-23 1 FOR PATENT |NFR|NGEMENT 4. United States Letters Patent No. 5,637,320 ("the '320 patent"…320 patent is attached hereto as Exhibit A. 5. Plaintiff Elan is the owner of the '320 patent. 6…expiration of the '320 patent was an act of infringement of the '320 patent. Case O:98-cv-O7164-A… COMPLAINT for patent infringement filed; FILING FEE $150.00 RECEIPT # 514809; A-7; LSS (Former …quot; _;,_ `-.` w l ~". (.».‘ COMPLA|NT FOR PATENT |NFR|NGEMENT ':p: §§ _,"" r\J External link to document
2004-06-01 274 the manufacturer of NAPROSYN®, owned U.S. Patent 3,998,966, directed to, inter a_lig, Case O:98-cv-O7164…offered to sell the patented invention more than one year prior to filing its patent application and that…application, E|an was issued U.S. Patent 5,637,320 on June 10, 1997. The ’320 patent includes one independent…'320 patent under 35 U.S.C. § 271(e)(2)(A). Andrx defended by arguing that E|an’s patent is invalid… matter of each claim of the patent was complete and ready for patenting at the time of the Lederle |etter External link to document
2009-03-09 326 hereby ordered that: 1. The claims of U.S. Patent No_. 5,637,320 are valid, enforceable and infringed by …1998 11 March 2009 0:98-cv-07164 830 Patent None District Court, S.D. Florida External link to document
2009-03-11 328 enjoined until the expiration of U.S. Patent No. 5,637,320 (“the ‘320 patent”), or final, non- appealable finding… ‘320 patent, or iinal, non~appe_alable finding of invalidity of the claims of the ‘320 patent from manufacturing…Infringing Product prior to the expiration of the ’320 patent, including replacing its Cer`tifications under …1998 11 March 2009 0:98-cv-07164 830 Patent None District Court, S.D. Florida External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Deloitte
AstraZeneca
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.